Skip to main content
. 2019 Sep 30;9(12):2025–2040. doi: 10.1002/2211-5463.12650

Figure 2.

Figure 2

(A,B) Efflux pump modulatory potential of UA in clinical isolate MRSA‐2071 using EtBr as marker, determined through spectrofluorometric analysis (A) and flow cytometric analysis (B). Reserpine, an efflux pump inhibitor, was used as positive control in both the experiments. (C) Expression analysis of efflux pump genes in the presence of UA alone and in combination with norfloxacin.